Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 1 Interventional

A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors

ClinicalTrials.gov ID: NCT05957536

Public ClinicalTrials.gov record NCT05957536. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Open-label Dose Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3L-001 Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors.

Study identification

NCT ID
NCT05957536
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
D3 Bio (Wuxi) Co., Ltd
Industry
Enrollment
128 participants

Conditions and interventions

Interventions

  • D3L-001 Biological

Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 18, 2023
Primary completion
Dec 18, 2028
Completion
Dec 18, 2028
Last update posted
Mar 12, 2026

2023 – 2028

United States locations

U.S. sites
4
U.S. states
4
U.S. cities
4
Facility City State ZIP Site status
D3 Bio Investigative Site Stanford California 94305 Recruiting
D3 Bio Investigative Site Boston Massachusetts 02215 Recruiting
D3 Bio Investigative Site New York New York 10065 Recruiting
D3 Bio Investigative Site San Antonio Texas 78229 Terminated

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05957536, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 12, 2026 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05957536 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →